Physiological roles of 11β-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase
- 1 August 2008
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Pediatrics
- Vol. 20 (4), 453-457
- https://doi.org/10.1097/mop.0b013e328305e439
Abstract
Inactive cortisone is converted to active cortisol by the reductase activity of 11 beta-hydroxysteroid dehydrogenase type 1, which can thus increase glucocorticoid effects in target tissues. This paper reviews the functional role(s) of 11 beta-hydroxysteroid dehydrogenase type 1 and examines factors influencing its activity. In obese humans, 11 beta-hydroxysteroid dehydrogenase type 1 is relatively highly expressed in adipose tissue. In mice, overexpression of 11 beta-hydroxysteroid dehydrogenase type 1 in adipose or liver causes obesity or insulin resistance, respectively, whereas mice lacking 11 beta-hydroxysteroid dehydrogenase type 1 resist diet-induced obesity and are insulin-sensitive. Thus, 11 beta-hydroxysteroid dehydrogenase type 1 is a promising drug target for treating the metabolic syndrome and type 2 diabetes. Studies in vitro and in mutant mice demonstrate that the reductase activity of 11 beta-hydroxysteroid dehydrogenase type 1 depends on reduced nicotinamide adenine dinucleotide phosphate synthesized within the endoplasmic reticulum by hexose-6-phosphate dehydrogenase. Apparent cortisone reductase deficiency is characterized by androgen excess in women or children and decreased urinary excretion of cortisol metabolites. Although polymorphisms in the genes encoding 11 beta-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase were initially implicated in this condition, subsequent reports have not confirmed this. Hexose-6-phosphate dehydrogenase and 11 beta-hydroxysteroid dehydrogenase type 1 may play important roles in the pathogenesis of obesity and metabolic syndrome. Although the importance of polymorphisms in the corresponding genes remains uncertain, rare mutations have not been ruled out.Keywords
This publication has 31 references indexed in Scilit:
- 11β‐HSD Type 1 Expression in Human Adipose Tissue: Impact of Gender, Obesity, and Fat LocalizationObesity, 2007
- 11β‐Hydroxysteroid Dehydrogenase Type 1 mRNA is Increased in Both Visceral and Subcutaneous Adipose Tissue of Obese PatientsObesity, 2006
- 11β-Hydroxysteroid Dehydrogenase Type 1: A Tissue-Specific Regulator of Glucocorticoid ResponseEndocrine Reviews, 2004
- Metabolic syndrome without obesity: Hepatic overexpression of 11β-hydroxysteroid dehydrogenase type 1 in transgenic miceProceedings of the National Academy of Sciences of the United States of America, 2004
- Regulation of 11β‐HSD Genes in Human Adipose Tissue: Influence of Central Obesity and Weight LossObesity Research, 2004
- Expression of 11β-Hydroxysteroid Dehydrogenase Type 1 in Adipose Tissue Is Not Increased in Human ObesityJournal of Clinical Endocrinology & Metabolism, 2002
- A Transgenic Model of Visceral Obesity and the Metabolic SyndromeScience, 2001
- 11β-Hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stressProceedings of the National Academy of Sciences of the United States of America, 1997
- 11β-Hydroxysteroid Dehydrogenase and the Syndrome of Apparent Mineralocorticoid Excess*Endocrine Reviews, 1997
- Expression of 11β-Hydroxysteroid Dehydrogenase Using Recombinant Vaccinia VirusMolecular Endocrinology, 1990